Índice Bovespa

US Dollar vs BRL

Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Allos Therapeutics, Inc. (MM) (ALTH)
Allos Therapeutics, Inc. (MM) (ALTH) Notícias

ALTH

Allos Therapeutics, Inc. (MM) (ALTH)

Allos Therapeutics, Inc. (MM)

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:NASDAQ:ALTH

<< Anterior 2 3 4 5 6 7 8 9 10 11 12 13 14 Próxima >>

Data	Hora	Fonte	Título	Código	Companhia
01/02/2006	11:00	PR Newswire (US)	Allos Therapeutics to Present at the 2006 BIO CEO & Investor Conference	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
16/01/2006	22:22	PR Newswire (US)	Allos Therapeutics Announces CEO Succession Plans	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
03/01/2006	11:00	PR Newswire (US)	Results Published in Journal of Clinical Oncology Affirm Survival Benefit of EFAPROXYN(TM) in Patients with Brain Metastases Ori	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
12/12/2005	11:02	PR Newswire (US)	Retrospective Analysis Finds EFAPROXYN(TM) Extends Survival With Quality of Life in Patients With Brain Metastases Originating F	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
12/12/2005	11:00	PR Newswire (US)	PDX Shows Promising Activity in Patients With Resistant T-Cell Lymphomas	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
17/11/2005	11:02	PR Newswire (US)	Allos Therapeutics Appoints Timothy P. Lynch to Board of Directors	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
17/11/2005	11:01	PR Newswire (US)	Interim Phase 1 Data on RH1 Presented at AACR-NCI-EORTC Conference	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
16/11/2005	11:00	PR Newswire (US)	Data From Phase 1 Clinical Trial of PDX (Pralatrexate) to be Presented at American Society of Hematology Annual Meeting	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
09/11/2005	11:02	PR Newswire (US)	Allos Therapeutics Reports Third Quarter 2005 Financial Results	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
08/11/2005	11:02	PR Newswire (US)	Data on EFAPROXYN(TM) and RH1 to be Presented at Upcoming Scientific Conferences	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
21/10/2005	14:02	PR Newswire (US)	Allos Therapeutics Announces Dismissal of Securities Class Action Lawsuit	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
13/10/2005	10:01	PR Newswire (US)	Allos Therapeutics to Present at the 2005 BIO Investor Forum	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
11/10/2005	19:06	PR Newswire (US)	Allos Therapeutics Announces Withdrawal of European Marketing Authorization Application for REVAPROXYN(TM)	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
22/09/2005	10:00	PR Newswire (US)	Allos Therapeutics to Present at the UBS Global Life Sciences Conference	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
07/09/2005	10:02	PR Newswire (US)	Allos Therapeutics to Present at the Bear Stearns Healthcare Conference	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
01/09/2005	10:00	PR Newswire (US)	Results Published in Journal of Clinical Oncology Demonstrate Survival Benefit of EFAPROXYN(TM) in Treating NSCLC Patients Recei	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
08/08/2005	10:01	PR Newswire (US)	Allos Therapeutics Reports Second Quarter 2005 Financial Results	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
16/06/2005	16:28	PR Newswire (US)	Allos Therapeutics and Hovione Enter Into Manufacturing Agreement for EFAPROXYN(TM) Bulk Drug Substance	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
19/05/2005	19:46	PR Newswire (US)	Allos Therapeutics Announces Stockholder Approval of Share Exchange	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
19/05/2005	10:00	PR Newswire (US)	Allos Therapeutics to Present at the Needham & Company Biotechnology Conference	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
05/05/2005	10:01	PR Newswire (US)	Allos Therapeutics Reports First Quarter 2005 Financial Results	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
11/03/2005	08:00	PR Newswire (US)	Allos Therapeutics to Present at SG Cowen's Healthcare Conference	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
03/03/2005	08:02	PR Newswire (US)	Allos Therapeutics Reports 2004 Financial Results	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
03/03/2005	08:00	PR Newswire (US)	Allos Therapeutics Announces $50 Million Financing	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
20/01/2005	11:00	PR Newswire (US)	Allos Therapeutics Initiates Phase 1 PDX Study in Patients With Non-Small Cell Lung Cancer	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
06/01/2005	11:01	PR Newswire (US)	Allos Therapeutics Announces Expansion of ENRICH Trial Into Europe	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
16/12/2004	11:00	PR Newswire (US)	Allos Therapeutics Licenses New Cancer Compound	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
09/12/2004	14:38	PR Newswire (US)	Allos Therapeutics Investigator Presents Updated Survival Results From Phase III REACH Study at San Antonio Breast Cancer Sympos	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
17/11/2004	09:00	PR Newswire (US)	Allos Therapeutics to Present at Credit Suisse First Boston's Healthcare Conference	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
11/11/2004	11:01	PR Newswire (US)	Allos Therapeutics Announces Presentation on EFAPROXYN(TM) at Chemotherapy Foundation Symposium XXII	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)

Apresentando as notícias mais relevantes sobre:NASDAQ:ALTH

<< Anterior 2 3 4 5 6 7 8 9 10 11 12 13 14 Próxima >>

Asiamet Resources

Vermilion Energy

Cimco Marine Ab

Macquarie Gp 31

Iv Ust 1-3 D Gb

Ballard Power Systems

DXI Capital (CE)

Vycor Medical (QB)

Reviva Pharmaceuticals

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições